Moderna impresses on the financial side as well in Q2

Moderna shares rose 1.5% immediately following the announcement. MRNA stock is one of the top performers this year, rising 310% since January.

Looking forward to listening to management/ analyst comments on Q2 results? Stay tuned here for Moderna Q2 2020 earnings call transcript

Moderna said it has received about $400 million in customer deposits for the potential supply of its Phase 3 Covid-19 vaccine mRNA-1273.

CEO Stéphane Bancel said, “As we pivot to a commercial-stage company, we recognize the need for responsible pricing in the face of the pandemic. We look forward to continuing our progress as we prepare for the Phase 3 readout and the expected subsequent filing of our BLA.”

Enrollment is ongoing for the Phase 3 COVE study.

Last month, the company had provided Phase 1 interim results, besides announcing the start of Phase 3 trials on July 27.  

[irp posts=”65979″]

____